Mumbai-based leading IVD company, Transasia Bio-Medicals Ltd. has acquired two more US based companies - Drew Scientific and JAS Diagnostics Inc. from Escalon Medical. This is the fifth acquisition made by Transasia in the year 2012. The acquisition was done through Transasia’s subsidiary, Erba Diagnostics USA. It has acquired the entire business assets including plant and intellectual assets, which will become a direct wholly-owned subsidiary of Erba Diagnostics.

Transasia Group’s acquisition of Drew marks the entry in the fast growing segment of diabetes management worldwide. It would benefit with the capabilities to offer proprietary liquid chromatography based glycated haemoglobin analyzers and reagents to the laboratories worldwide. Glycated haemoglobin analysis by liquid chromatography is the method of choice in monitoring long term glycemic control in diabetics.

JAS Diagnostics Inc. is a manufacturer of clinical chemistry reagents. It supplies chemistry reagents that it has developed through its own indigenous R&D. It offers solutions with excellent stability in different formats of systems packs, liquid reagents and powder reagents.

According to sources, diabetes affects an estimated 250 million people worldwide with nearly 60 per cent residing in India and China alone. An estimated 90 million people are affected in China followed by 60 million in India and 25 million people are affected in North America signalling a huge opportunity and the strategic nature of this acquisition.

“The acquisition was a natural consequence of its focus on the challenges posed by the vast and fast growing diabetes monitoring segment,” said Suresh Vazirani, chairman and managing director, Transasia Bio-Medicals Ltd.  “It is also to address the lack of quality solutions and supply options in India specifically and worldwide in the monitoring of long term glycemic control,” he added.

Transasia is already a leading player in the field of autoimmune and Infectious diseases testing in North America with proprietary Mago platform and Immunosimplicity range of Immunoassays. With this acquisition, Transasia will also foray in the lucrative physician/doctor’s office segment of clinical chemistry, haematology instruments and reagents in North America.

The company has laid out plans to expand its markets for existing range of diabetes management, haematology and clinical chemistry in the rest of the world, leveraging its direct presence in USA, Italy, Eastern Europe, Russian federation, Turkey and its distribution partners in 90 countries worldwide. Transasia plans to offer range of automated solutions in Clinical Chemistry in the North American market.

With this strategic acquisition, Transasia, has deftly complimented and combined the innovative and advanced products development capability of Drew with the marketing and distribution expertise of Transasia. Transasia has already started mapping the future developmental goals for newer more advanced analyzers in diabetes, haematology and clinical chemistry with the enhanced developmental and intellectual capital from the current acquisition.